It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with placebo (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with placebo (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in maintenance of remission compared with mesalazine or sulfasalazine (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes adverse events compared with mesalazine or sulfasalazine (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with mesalazine or sulfasalazine (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with mesalazine or sulfasalazine (very low certainty).
It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 6‐mercaptopurine (very low certainty).
It is very uncertain whether methotrexate changes proportion of patients maintaining clinical remission compared with 6‐mercaptopurine (very low certainty).
Azathioprine may leads to lower failure to maintain remission compared with placebo (low certainty).
It is very uncertain whether the intervention changes acute pancreatitis (very low certainty).
It is very uncertain whether the intervention changes bone marrow suppression (very low certainty).
It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).
It is very uncertain whether azathioprine changes withdrawal due to adverse event compared with placebo (very low certainty).
It is very uncertain whether azathioprine changes failure to maintain remission compared with sulfasalazine (very low certainty).
It is very uncertain whether azathioprine (AZA) changes failure to maintain remission compared with cyclosporin of remission (very low certainty).
It is very uncertain whether the intervention changes any adverse event (very low certainty).
It is very uncertain whether the intervention changes withdrawal due to adverse event (very low certainty).
Azathioprine showed no clear difference in adverse events compared with infliximab (moderate certainty).
Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).